Triple-Positive
Overview of triple-positive breast cancer, including what it is and where relevant support threads and overlapping subtype resources currently live
This section is for triple-positive breast cancer topics.
Triple-positive breast cancer means the cancer is:
ER-positive
PR-positive
HER2-positive
That combination means it sits at the overlap of two major treatment logics:
endocrine / receptor-positive treatment questions
HER2-targeted treatment questions
That is why this subtype often needs its own home, even when some of the most useful material still overlaps with the ER-positive and HER2-positive sections.
What this subtype usually raises
Triple-positive disease often brings a mixed set of questions, such as:
how ER and HER2 signalling interact
when endocrine resistance matters
how HER2-targeted therapy changes the picture
how subtype labels like luminal B may overlap with treatment thinking
where support threads sit when a question is partly endocrine and partly HER2-driven
Relevant support group threads and docs
Triple-positive-specific thread
Current overlap pages are worth checking
Until this section grows further, the most relevant overlap pages currently live in the HER2-Positive and ER-Positive / HER2-Negative sections.
More HER2-linked material
More ER-linked material
How this section will grow
This section will expand to include:
triple-positive-treatment-specific resistance questions
endocrine-plus-HER2 treatment overlap notes
support-thread links pulled across from both ER-positive and HER2-positive sections
subtype-specific practical questions on sequencing, side effects, and adjunctive support